We are the first company using microRNA therapy for ophthalmic diseases in humans. Our core product, miRNA-328 inhibitor, targets myopia, dry eye disease, and corneal erosion. Currently, all indications have progressed to Phase II clinical trials or are about to Phase III clinical trials.
